Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials

Psoriasis

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial

JAMA Dermatol

Gooderham MJ, Alonso-Llamazares J, Bagel J, Bhatia N, Bukhalo M, DuBois J, Ferris LK, Green L, Kircik LH, Lockshin B, Loo WJ, Papp KA, Soung J, Seal MS, Snyder S, Kato S, Krupa D, Burnett P, Berk DR, Chu DH

doi: 10.1001/jamadermatol.2025.1136

Atopic Dermatitis

Remibrutinib in chronic spontaneous urticaria: 52-Week results from two phase 3 studies

J Allergy Clin Immunol

Giménez-Arnau AM, Szalewski R, Hide M, Jain V, Khemis A, Lebwohl M, Metz M, Mosnaim G, Palumbo M, Şavk E, Sussman G, Walecka-Herniczek I, Yang B, Field C, Haemmerle S, Lheritier K, Machado PGP, Martzloff ED, Seko N, Wang P, Zharkov A, Saini S

doi: 10.1016/j.jaci.2025.09.028

Melanoma and Skin Cancer

Radiotherapy Versus Imiquimod for Complex Lentigo Maligna: a Phase 3 Randomized Clinical Trial

J Am Acad Dermatol

Hong AM, Lo SN, Fogarty GB, Stretch J, Wang W, Fernandez-Penas P, Martin RC, Foote M, Soyer HP, Ruben J, Mar V, Rocha L, Festa-Neto C, Wratten C, Hogarth S, Collgros H, Glanz A, Gouveia BM, Scolyer RA, King MT, Guitera P

doi: 10.1016/j.jaad.2025.07.028

Further Publications Immunology

Improving Empiric Antibiotic Selection for Patients Hospitalized With Skin and Soft Tissue Infection: The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial

JAMA Intern Med

Gohil SK, Septimus E, Kleinman K, Varma N, Sands KE, Avery TR, Mauricio A, Sljivo S, Rahm R, Roemer K, Cooper WS, McLean LE, Nickolay NG, Poland RE, Weinstein RA, Fakhry SM, Guy J, Moody J, Coady MH, Smith KN, Meador B, Froman A, Eibensteiner K, Hayden MK, Kubiak DW, Burks C, Burgess LH, Calderwood MS, Perlin JB, Platt R, Huang SS

doi: 10.1001/jamainternmed.2025.0887

Immune Response

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

N Engl J Med

Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, Floege J, Jha V, Kim BS, Liew A, Maes B, Pal A, Pecoits-Filho R, Phoon RKS, Rizk DV, Suzuki H, Tesař V, Trimarchi H, Wei X, Zhang H, Barratt J, ORIGIN Phase 3 Trial Investigators

doi: 10.1056/NEJMoa2510198

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Further Publications Dermatology

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Lancet

Luckey A, Balasegaram M, Barbee LA, Batteiger TA, Broadhurst H, Cohen SE, Delany-Moretlwe S, de Vries HJC, Dionne JA, Gill K, Kenyon C, Kittiyaowamarn R, Lewis D, Mueller JP, Naicker V, O'Brien S, O'Donnell JP, Phanuphak N, Spooner E, Srinivasan S, Taylor SN, Unemo M, Zwane Z, Hook EW 3rd, Zoliflodacin Phase 3 Study Group

doi: 10.1016/S0140-6736(25)01953-1

Further Publications Dermatology

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial

JAMA Dermatol

Ständer S, Yosipovitch G, Sofen H, Abramzon D, Galanter J, Wang S, Paolini JF

doi: 10.1001/jamadermatol.2025.4950

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Related content

Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial

Remibrutinib in chronic spontaneous urticaria: 52-Week results from two phase 3 studies

Radiotherapy Versus Imiquimod for Complex Lentigo Maligna: a Phase 3 Randomized Clinical Trial

Improving Empiric Antibiotic Selection for Patients Hospitalized With Skin and Soft Tissue Infection: The INSPIRE 3 Skin and Soft Tissue Randomized Clinical Trial

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Vixarelimab in Patients With Prurigo Nodularis: A Randomized Clinical Trial

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)